March 4, 2016

Meridien Research Completes Add-on Acquisition

We are pleased to announce the acquisition of the Bradenton, FL clinic of Florida Clinical Research Center (“FCRC’) by Meridien Research, a Celerity portfolio company.¬† Meridien conducts clinical trials for new drug development on behalf of CROs and pharmaceutical companies. The addition of FCRC Bradenton brings our total number of clinics to six, and materially expands Meridien’s CNS trial activity and therapeutic area coverage across a broad range of CNS indications, from Alzheimer’s to schizophrenia. Dr. Andrew Cutler, the owner and Principal Investigators of FCRC, and a psychiatrist of national repute, will be joining Meridien as Chief Medical Officer.